Plus Therapeutics Phase 2 GBM trial: mOS 13 mo (63% above SOC), mPFS 11 mo

PLUS THERAPEUTICS, INC.

Median overall survival 13 months in 15 rGBM patients, 63% better than SOC bevacizumab (8 mo).
Median progression-free survival 11 months vs SOC 4 months; 9 of 15 patients remain alive.
Delivers up to 20x radiation dose (740 Gy) vs EBRT (35 Gy); favorable safety profile maintained.
Imaging analysis confirms efficacy signal; company to host KOL webinar Nov 20 at 10 am ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.